SCHEMBL6447175

SCHEMBL6447175

Cn1nnc(-c2ccc(NC(=O)c3ccc(C(=O)Nc4nnc(-c5cc(Cl)cc(Cl)c5O)s4)cc3)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CSNK2A2 P19784 3/20 0.40
CSNK2A1 P68400 3/20 0.40
PTGER3 P43115 2/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
PTPN7 P35236 1/20 0.39
BRCA1 P38398 1/20 0.39
DUSP3 P51452 1/20 0.39
PTPN11 Q06124 1/20 0.39
WNT3A P56704 1/20 0.39
XDH P47989 2/20 0.39
KDM4E B2RXH2 3/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325791 0.91 BLM (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL6447202 0.84 KMT2A (0.46) NPC1RAB9ASMN1; SMN2PTGER3XDH
SCHEMBL6449238 0.84 CSNK2A2 (0.52) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1
SCHEMBL6445872 0.83 NPC1 (0.53) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1
SCHEMBL6444242 0.83 RAB9A (0.52) NPC1RAB9ASMN1; SMN2PTGER3ALDH1A1
SCHEMBL6445978 0.83 SNCA (0.47) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1
SCHEMBL6451642 0.83 WNT3A (0.39) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1
SCHEMBL6445912 0.83 ALDH1A1 (0.50) NPC1RAB9ACSNK2A2CSNK2A1PTGER3
SCHEMBL6447053 0.82 CSNK2A2 (0.49) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1
SCHEMBL6445760 0.82 CSNK2A2 (0.52) NPC1RAB9ASMN1; SMN2CSNK2A2CSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 NPC1 1404/4885RAB9A 1792/4885SMN1; SMN2 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.